Core Viewpoint - Boston Scientific Corporation (NYSE:BSX) is recognized as one of the best large-cap stocks to invest in, with UBS reiterating a Buy rating and maintaining a price target of $140 despite recent share price declines [1]. Group 1: Analyst Insights - UBS analyst Danielle Antalffy indicates that the risk/reward profile for Boston Scientific is increasingly favorable as it approaches 2026, supported by high-growth business areas sustaining momentum [2]. - The Electrophysiology (EP) division, accounting for approximately 17% of the company's estimated sales in 2025, is expected to slow in 2026; however, CEO Mike Mahoney aims to grow this division at rates higher than the market's estimated 20-25% [3]. - CEO Mahoney expresses confidence in achieving sustained double-digit growth for the WATCHMAN device, which is projected to represent about 10% of estimated sales in 2025, even ahead of the CHAMPION data readout expected in spring 2026 [4]. Group 2: Company Overview - Boston Scientific Corporation is an American biotechnology and biomedical engineering company that provides a range of devices and therapies for diagnosing and treating various diseases, including cardiovascular, respiratory, digestive, oncological, neurological, and urological conditions [5].

Group 1 - Boston Scientific Corporation (NYSE:BSX) is recognized as one of the best long-term stocks to buy, with UBS maintaining a Buy rating and raising the price target to $140 from $135 following strong quarterly results [1] - The company reported net revenue of $5,065 million for Q3, reflecting a 15.3% year-over-year organic growth, and adjusted earnings per share of $0.75, exceeding the consensus estimate of $0.71 [2] - Boston Scientific has increased its full-year 2025 outlook, now projecting approximately 20% growth and adjusted EPS of $3.02-$3.04, an increase from previous estimates [2] Group 2 - The FARAPULSE product line experienced approximately 63% organic worldwide expansion, with US growth improving by 40 percentage points on a comp-adjusted basis [3] - The WATCHMAN device achieved 35% organic sales growth for the fifth consecutive quarter, indicating increasing product acceptance [3] Group 3 - Boston Scientific Corporation is a global leader in manufacturing medical devices, including stents, brain stimulation systems, heart monitors, and catheters [4]